Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150


Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii).

Patchett AL, Coorens THH, Darby J, Wilson R, McKay MJ, Kamath KS, Rubin A, Wakefield M, Mcintosh L, Mangiola S, Pye RJ, Flies AS, Corcoran LM, Lyons AB, Woods GM, Murchison EP, Papenfuss AT, Tovar C.

Cell Mol Life Sci. 2019 Aug 2. doi: 10.1007/s00018-019-03259-2. [Epub ahead of print]


Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures.

Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA.

Res Pract Thromb Haemost. 2019 May 17;3(3):372-382. doi: 10.1002/rth2.12205. eCollection 2019 Jul.


Editorial: Wild Immunology-The Answers Are Out There.

Flies AS, Woods GM.

Front Immunol. 2019 Jan 30;10:126. doi: 10.3389/fimmu.2019.00126. eCollection 2019. No abstract available.


Inducible IFN-γ Expression for MHC-I Upregulation in Devil Facial Tumor Cells.

Ong CEB, Lyons AB, Woods GM, Flies AS.

Front Immunol. 2019 Jan 14;9:3117. doi: 10.3389/fimmu.2018.03117. eCollection 2018.


TNF May Negatively Regulate Phagocytosis of Devil Facial Tumour Disease Cells by Activated Macrophages.

Li X, Darby J, Lyons AB, Woods GM, Körner H.

Immunol Invest. 2019 Oct;48(7):691-703. doi: 10.1080/08820139.2018.1515222. Epub 2019 Jan 19.


The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease.

Kosack L, Wingelhofer B, Popa A, Orlova A, Agerer B, Vilagos B, Majek P, Parapatics K, Lercher A, Ringler A, Klughammer J, Smyth M, Khamina K, Baazim H, de Araujo ED, Rosa DA, Park J, Tin G, Ahmar S, Gunning PT, Bock C, Siddle HV, Woods GM, Kubicek S, Murchison EP, Bennett KL, Moriggl R, Bergthaler A.

Cancer Cell. 2019 Jan 14;35(1):125-139.e9. doi: 10.1016/j.ccell.2018.11.018.


Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study.

Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R.

Pediatr Blood Cancer. 2019 Apr;66(4):e27588. doi: 10.1002/pbc.27588. Epub 2018 Dec 13.


Liposomal Bupivacaine Utilization in Total Knee Replacement Does Not Decrease Length of Hospital Stay.

Schumer G, Mann JW 3rd, Stover MD, Sloboda JF, Cdebaca CS, Woods GM.

J Knee Surg. 2019 Sep;32(9):934-939. doi: 10.1055/s-0038-1673617. Epub 2018 Oct 29.


Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding.

Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH.

Pediatr Dev Pathol. 2019 Mar-Apr;22(2):123-127. doi: 10.1177/1093526618803838. Epub 2018 Oct 9.


Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.

Woods GM, Fox S, Flies AS, Tovar CD, Jones M, Hamede R, Pemberton D, Lyons AB, Bettiol SS.

Integr Comp Biol. 2018 Dec 1;58(6):1043-1054. doi: 10.1093/icb/icy118.


The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer.

Caldwell A, Coleby R, Tovar C, Stammnitz MR, Kwon YM, Owen RS, Tringides M, Murchison EP, Skjødt K, Thomas GJ, Kaufman J, Elliott T, Woods GM, Siddle HV.

Elife. 2018 Aug 14;7. pii: e35314. doi: 10.7554/eLife.35314.


Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease.

Tovar C, Patchett AL, Kim V, Wilson R, Darby J, Lyons AB, Woods GM.

PLoS One. 2018 Apr 27;13(4):e0196469. doi: 10.1371/journal.pone.0196469. eCollection 2018.


Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells.

Patchett AL, Wilson R, Charlesworth JC, Corcoran LM, Papenfuss AT, Lyons BA, Woods GM, Tovar C.

Oncotarget. 2018 Mar 23;9(22):15895-15914. doi: 10.18632/oncotarget.24634. eCollection 2018 Mar 23.


The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils.

Stammnitz MR, Coorens THH, Gori KC, Hayes D, Fu B, Wang J, Martin-Herranz DE, Alexandrov LB, Baez-Ortega A, Barthorpe S, Beck A, Giordano F, Knowles GW, Kwon YM, Hall G, Price S, Pye RJ, Tubio JMC, Siddle HVT, Sohal SS, Woods GM, McDermott U, Yang F, Garnett MJ, Ning Z, Murchison EP.

Cancer Cell. 2018 Apr 9;33(4):607-619.e15. doi: 10.1016/j.ccell.2018.03.013.


Maternal exposure to particulate matter alters early post-natal lung function and immune cell development.

Chen L, Bennett E, Wheeler AJ, Lyons AB, Woods GM, Johnston F, Zosky GR.

Environ Res. 2018 Jul;164:625-635. doi: 10.1016/j.envres.2018.03.029. Epub 2018 Apr 5.


Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study.

Woods GM, Sharma R, Creary S, O'Brien S, Stanek J, Hor K, Young J, Dunn AL, Kumar R.

J Pediatr. 2018 Jun;197:186-190.e1. doi: 10.1016/j.jpeds.2018.01.073. Epub 2018 Mar 28.


Gomesin peptides prevent proliferation and lead to the cell death of devil facial tumour disease cells.

Fernandez-Rojo MA, Deplazes E, Pineda SS, Brust A, Marth T, Wilhelm P, Martel N, Ramm GA, Mancera RL, Alewood PF, Woods GM, Belov K, Miles JJ, King GF, Ikonomopoulou MP.

Cell Death Discov. 2018 Feb 14;4:19. doi: 10.1038/s41420-018-0030-0. eCollection 2018 Dec.


Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.

Pye R, Patchett A, McLennan E, Thomson R, Carver S, Fox S, Pemberton D, Kreiss A, Baz Morelli A, Silva A, Pearse MJ, Corcoran LM, Belov K, Hogg CJ, Woods GM, Lyons AB.

Front Immunol. 2018 Feb 19;9:259. doi: 10.3389/fimmu.2018.00259. eCollection 2018.


Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience.

Woods GM, Stanek J, Harrison S, Texter K, Kerlin BA, Dunn AL, Kumar R.

J Pediatr Hematol Oncol. 2017 Oct;39(7):576-577. doi: 10.1097/MPH.0000000000000966. No abstract available.


The toll-like receptor ligands Hiltonol® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii).

Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM.

Dev Comp Immunol. 2017 Nov;76:352-360. doi: 10.1016/j.dci.2017.07.004. Epub 2017 Jul 6.


The absence of TNF permits myeloid Arginase 1 expression in experimental L. monocytogenes infection.

Li X, Lyons AB, Woods GM, Körner H.

Immunobiology. 2017 Aug;222(8-9):913-917. doi: 10.1016/j.imbio.2017.05.012. Epub 2017 May 16.


Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.

Flies AS, Blackburn NB, Lyons AB, Hayball JD, Woods GM.

Front Immunol. 2017 May 3;8:513. doi: 10.3389/fimmu.2017.00513. eCollection 2017.


Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.

Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, Malley RC, Siddle HV, Skjødt K, Kaufman J, Silva A, Baz Morelli A, Papenfuss AT, Corcoran LM, Murphy JM, Pearse MJ, Belov K, Lyons AB, Woods GM.

Sci Rep. 2017 Mar 9;7:43827. doi: 10.1038/srep43827.


Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.

Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM.

Biol Lett. 2016 Oct;12(10). pii: 20160553. doi: 10.1098/rsbl.2016.0553.


PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.

Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, Knowles GW, Woods GM, Hayball JD.

Front Immunol. 2016 Dec 9;7:581. doi: 10.3389/fimmu.2016.00581. eCollection 2016.


The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines.

Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM.

PLoS One. 2016 Dec 9;11(12):e0168068. doi: 10.1371/journal.pone.0168068. eCollection 2016.


Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases.

Thompson JC, Woods GM, Arnold MA, Elmaraghy C, Kahwash SB, Cripe TP, Setty BA.

Case Rep Oncol. 2016 Aug 17;9(2):447-453. eCollection 2016 May-Aug.


Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by Metabolic Profiling of Serum.

Karu N, Wilson R, Hamede R, Jones M, Woods GM, Hilder EF, Shellie RA.

J Proteome Res. 2016 Oct 7;15(10):3827-3840. Epub 2016 Sep 23.


Light Transmission Aggregometry Does Not Correlate With the Severity of δ-Granule Platelet Storage Pool Deficiency.

Woods GM, Kudron EL, Davis K, Stanek J, Kerlin BA, O'Brien SH.

J Pediatr Hematol Oncol. 2016 Oct;38(7):525-8. doi: 10.1097/MPH.0000000000000638.


Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.

Atashrazm F, Lowenthal RM, Dickinson JL, Holloway AF, Woods GM.

Oncotarget. 2016 Jul 19;7(29):46028-46041. doi: 10.18632/oncotarget.10016.


Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.

Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, Murphy JM, Corcoran LM, Bettiol SS, Lyons AB, Woods GM.

Immunol Cell Biol. 2016 Aug;94(7):673-9. doi: 10.1038/icb.2016.38. Epub 2016 Apr 19.


A second transmissible cancer in Tasmanian devils.

Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, Fox S, Darby J, Hayes D, Knowles GW, Kreiss A, Siddle HV, Swift K, Lyons AB, Murchison EP, Woods GM.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):374-9. doi: 10.1073/pnas.1519691113. Epub 2015 Dec 28.


Devil Facial Tumor Disease.

Pye RJ, Woods GM, Kreiss A.

Vet Pathol. 2016 Jul;53(4):726-36. doi: 10.1177/0300985815616444. Epub 2015 Dec 13. Review.


Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and In Vivo.

Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Karpiniec SS, Dickinson JL.

J Cell Physiol. 2016 Mar;231(3):688-97. doi: 10.1002/jcp.25119.


Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil.

Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, Woods GM.

Dev Comp Immunol. 2015 Nov;53(1):123-33. doi: 10.1016/j.dci.2015.07.003. Epub 2015 Jul 13.


Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.

Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, Corcoran LM, Lyons AB.

J Immunol. 2015 Jul 1;195(1):23-9. doi: 10.4049/jimmunol.1500131. Review.


A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents.

Woods GM, Kerlin BA, O'Brien SH, Bonny AE.

J Pediatr Adolesc Gynecol. 2016 Oct;29(5):402-408. doi: 10.1016/j.jpag.2015.05.007. Epub 2015 May 30. Review.


Fucoidan and cancer: a multifunctional molecule with anti-tumor potential.

Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Dickinson JL.

Mar Drugs. 2015 Apr 14;13(4):2327-46. doi: 10.3390/md13042327. Review.


Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma.

Woods GM, Bondra K, Chronowski C, Leasure J, Singh M, Hensley L, Cripe TP, Chakravarti A, Houghton P.

Pediatr Blood Cancer. 2015 Sep;62(9):1550-1554. doi: 10.1002/pbc.25516. Epub 2015 Mar 19.


Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.

Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM.

Vaccine. 2015 Jun 12;33(26):3016-25. doi: 10.1016/j.vaccine.2015.01.039. Epub 2015 Feb 20.


Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF.

N Engl J Med. 2014 Aug 21;371(8):699-710. doi: 10.1056/NEJMoa1401731.


Silent cerebral infarction, income, and grade retention among students with sickle cell anemia.

King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR.

Am J Hematol. 2014 Oct;89(10):E188-92. doi: 10.1002/ajh.23805. Epub 2014 Aug 4.


Mouse Model of Devil Facial Tumour Disease Establishes That an Effective Immune Response Can be Generated Against the Cancer Cells.

Pinfold TL, Brown GK, Bettiol SS, Woods GM.

Front Immunol. 2014 May 27;5:251. doi: 10.3389/fimmu.2014.00251. eCollection 2014.


Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm.

Woods GM, Bajwa RP, Kahwash SB, Guinipero T.

Case Rep Med. 2014;2014:473297. doi: 10.1155/2014/473297. Epub 2014 Mar 18.


Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors.

Howson LJ, Morris KM, Kobayashi T, Tovar C, Kreiss A, Papenfuss AT, Corcoran L, Belov K, Woods GM.

Anat Rec (Hoboken). 2014 May;297(5):925-38. doi: 10.1002/ar.22904. Epub 2014 Mar 24.


Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer.

Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng Y, Belov K, Swift K, Pearse AM, Hamede R, Jones ME, Skjødt K, Woods GM, Kaufman J.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5103-8. doi: 10.1073/pnas.1219920110. Epub 2013 Mar 11.


Ultraviolet radiation effects on the proteome of skin cells.

Muller HK, Woods GM.

Adv Exp Med Biol. 2013;990:111-9. doi: 10.1007/978-94-007-5896-4_8. Review.


Anti-PML-RARα shRNA sensitises promyelocytic leukaemia cells to all-trans retinoic acid.

Casey NP, Woods GM.

J RNAi Gene Silencing. 2012;8:464-9. Epub 2012 Jul 13.


Dietary vitamin D alters the response of the skin to UVB-irradiation depending on the genetic background of the mice.

Malley RC, Muller HK, Norval M, Woods GM.

Photochem Photobiol Sci. 2013 Mar;12(3):536-45. doi: 10.1039/c2pp25211b.


Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer.

Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ, Fu B, Hims M, Ding Z, Ivakhno S, Stewart C, Ng BL, Wong W, Aken B, White S, Alsop A, Becq J, Bignell GR, Cheetham RK, Cheng W, Connor TR, Cox AJ, Feng ZP, Gu Y, Grocock RJ, Harris SR, Khrebtukova I, Kingsbury Z, Kowarsky M, Kreiss A, Luo S, Marshall J, McBride DJ, Murray L, Pearse AM, Raine K, Rasolonjatovo I, Shaw R, Tedder P, Tregidgo C, Vilella AJ, Wedge DC, Woods GM, Gormley N, Humphray S, Schroth G, Smith G, Hall K, Searle SM, Carter NP, Papenfuss AT, Futreal PA, Campbell PJ, Yang F, Bentley DR, Evers DJ, Stratton MR.

Cell. 2012 Feb 17;148(4):780-91. doi: 10.1016/j.cell.2011.11.065.

Supplemental Content

Loading ...
Support Center